Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1966 1
1967 1
1970 2
1971 1
1974 1
1975 1
1976 1
1977 2
1979 1
1980 1
1982 2
1983 1
1984 2
1985 2
1986 2
1987 3
1989 1
1990 3
1991 2
1992 5
1993 2
1994 3
1995 6
1996 3
1997 6
1998 7
1999 4
2000 7
2001 3
2002 4
2003 5
2004 10
2005 5
2006 8
2007 11
2008 6
2009 9
2010 14
2011 15
2012 13
2013 11
2014 17
2015 16
2016 16
2017 20
2018 16
2019 23
2020 75
2021 75
2022 79
2023 59
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

531 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypogonadotropic hypogonadism 19 with or without anosmia"
Page 1
Parkinson's disease: etiopathogenesis and treatment.
Jankovic J, Tan EK. Jankovic J, et al. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. doi: 10.1136/jnnp-2019-322338. Epub 2020 Jun 23. J Neurol Neurosurg Psychiatry. 2020. PMID: 32576618 Review.
The concept of 'idiopathic' Parkinson's disease (PD) as a single entity has been challenged with the identification of several clinical subtypes, pathogenic genes and putative causative environmental agents. In addition to classic motor symptoms, non-motor manifestations ( …
The concept of 'idiopathic' Parkinson's disease (PD) as a single entity has been challenged with the identification of several clinical …
Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.
Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, Suen J, Robba C, Fraser J, Cho SM. Premraj L, et al. J Neurol Sci. 2022 Mar 15;434:120162. doi: 10.1016/j.jns.2022.120162. Epub 2022 Jan 29. J Neurol Sci. 2022. PMID: 35121209 Free PMC article. Review.
Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety, depression, dysgeusia, fatigue, headache, myalgia, and sleep disturbance at three (or more) months post-infection. ...Psychiatric manifestations (slee …
Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety, depression …
Nasal polyps and rhinosinusitis.
Kwah JH, Peters AT. Kwah JH, et al. Allergy Asthma Proc. 2019 Nov 1;40(6):380-384. doi: 10.2500/aap.2019.40.4252. Allergy Asthma Proc. 2019. PMID: 31690375 Review.
Nasal polyps typically present with nasal congestion, nasal obstruction, and anosmia or hyposmia, and occur more frequently in patients with persistent asthma, aspirin-exacerbated respiratory disease (AERD), CRS, and cystic fibrosis. ...
Nasal polyps typically present with nasal congestion, nasal obstruction, and anosmia or hyposmia, and occur more frequently in patien …
Chronic Rhinosinusitis.
Sedaghat AR. Sedaghat AR. Am Fam Physician. 2017 Oct 15;96(8):500-506. Am Fam Physician. 2017. PMID: 29094889 Free article. Review.
Chronic rhinosinusitis is defined by the presence of at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/anosmia, nasal drainage, and nasal obstruction) for at least 12 consecutive weeks, in addition to objective evidence. ...
Chronic rhinosinusitis is defined by the presence of at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/ano …
Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis.
Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, Patel U. Malik P, et al. J Med Virol. 2022 Jan;94(1):253-262. doi: 10.1002/jmv.27309. Epub 2021 Sep 7. J Med Virol. 2022. PMID: 34463956 Free PMC article.
We calculated the pooled prevalence with 95% confidence interval (CI) and created forest plots using random-effects models. A total of 12 studies with 4828 PCS patients were included. ...The prevalence of persistent symptoms was fatigue (64, 54-73), dyspnea (39.5, 20-60), …
We calculated the pooled prevalence with 95% confidence interval (CI) and created forest plots using random-effects models. A total o …
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.
Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, Lindsell K, Hare SS, Brown J, Frise R, Smith E, Hopkins C, Noulin N, Löndt B, Wilkinson T, Harden S, McShane H, Baillet M, Gilbert A, Jacobs M, Charman C, Mande P, Nguyen-Van-Tam JS, Semple MG, Read RC, Ferguson NM, Openshaw PJ, Rapeport G, Barclay WS, Catchpole AP, Chiu C. Killingley B, et al. Nat Med. 2022 May;28(5):1031-1041. doi: 10.1038/s41591-022-01780-9. Epub 2022 Mar 31. Nat Med. 2022. PMID: 35361992 Clinical Trial.
Mild-to-moderate symptoms were reported by 16 (89%) infected participants, beginning 2-4 days after inoculation, whereas two (11%) participants remained asymptomatic (no reportable symptoms). Anosmia or dysosmia developed more slowly in 15 (83%) participants. ...Future stu …
Mild-to-moderate symptoms were reported by 16 (89%) infected participants, beginning 2-4 days after inoculation, whereas two (11%) participa …
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J, Bachert C, Amin N, Desrosiers M, Hellings PW, Han JK, Jankowski R, Vodicka J, Gevaert P, Daizadeh N, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Mullol J, et al. J Allergy Clin Immunol Pract. 2022 Apr;10(4):1086-1095.e5. doi: 10.1016/j.jaip.2021.09.037. Epub 2021 Oct 7. J Allergy Clin Immunol Pract. 2022. PMID: 34628065 Free article. Clinical Trial.
OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. METHODS: In the randomized SINUS-24 and SINUS-52 studies, adults with severe CRSwNP received dupilumab 300 mg subcutaneously or matching placebo every 2 weeks for 24 or 52 weeks, respectively. …
OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. METHODS: In the randomized SINUS-24 and SINUS-52 stu …
Use of platelet-rich plasma for COVID-19-related olfactory loss: a randomized controlled trial.
Yan CH, Jang SS, Lin HC, Ma Y, Khanwalkar AR, Thai A, Patel ZM. Yan CH, et al. Int Forum Allergy Rhinol. 2023 Jun;13(6):989-997. doi: 10.1002/alr.23116. Epub 2022 Dec 21. Int Forum Allergy Rhinol. 2023. PMID: 36507615 Free PMC article. Clinical Trial.
INTRODUCTION: The current study evaluated the use of platelet-rich plasma (PRP), an autologous blood product with supraphysiologic concentrations of growth factors, in the treatment of prolonged coronavirus disease 2019 (COVID-19)-related smell loss. METHODS: This multi-instituti …
INTRODUCTION: The current study evaluated the use of platelet-rich plasma (PRP), an autologous blood product with supraphysiologic concentra …
Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
van der Lans RJL, Otten JJ, Adriaensen GFJPM, Hoven DR, Benoist LB, Fokkens WJ, Reitsma S. van der Lans RJL, et al. Allergy. 2023 Oct;78(10):2684-2697. doi: 10.1111/all.15796. Epub 2023 Jul 2. Allergy. 2023. PMID: 37394895
RESULTS: Mean scores (s.d.) of all co-primary outcomes improved significantly from baseline ( 228) to the 48 ( 214) and 96-weeks ( 99) timepoints: Nasal Polyp Score (0-8) improved from 5,3 (1,9) to 1,4 (1,8) and 1,3 (1,7); SinoNasal Outcome Test (SNOT)-22 (0-110) improved from 53 …
RESULTS: Mean scores (s.d.) of all co-primary outcomes improved significantly from baseline ( 228) to the 48 ( 214) and 96-weeks ( 99) timep …
Coronavirus Disease-19 and Rhinology/Facial Plastics.
Davis ME, Yan CH. Davis ME, et al. Otolaryngol Clin North Am. 2020 Dec;53(6):1139-1151. doi: 10.1016/j.otc.2020.08.002. Epub 2020 Aug 19. Otolaryngol Clin North Am. 2020. PMID: 33039097 Free PMC article. Review.
531 results